PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Alpine stops clinical study enrollment following patient deaths

Alpine Immune Sciences, Seattle-based biotech, announced this week that it would be voluntarily stopping the enrollment in two clinical trials studying a CD28 costimulator, following a second patient death.

The drug in question is davoceticept, an investigational dual checkpoint inhibitor, and CD28 conditional costimulator. Alpine had mostly shared promising results, with phase 1 studies showing that the drug had encouraging results, especially in renal cell carcinoma. The two trials paused, NEON-1 and NEON-2, studied davoceticept in combination with Merck’s Keytruda.

According to the recent announcement, the second patient death occurred in the NEON-2 study, attributed to cariogenic shock. The participant had metastatic colorectal cancer and had been previously treated with multiple systemic chemotherapies. The first patient’s death in the trial was attributed to cariogenic shock as well.

Alpine first came onto the scene in 2015, receiving $48 million in series A financing. The biotech’s proprietary platforms consist of unique protein engineering strategies, including the directed evolution of immune proteins into multi-targeted therapeutics.

According to Alpine, the company’s primary focus will now be the development of its dual B cell cytokine antagonist, ALPN-303, against multiple autoimmune and inflammatory diseases.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026